Find Dexpramipexole manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 104632-28-2, (r)-pramipexole, (r)-n6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine, R-(+)-pramipexole, (6r)-6-n-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine, Wi638gus96
Molecular Formula
C10H17N3S
Molecular Weight
211.33  g/mol
InChI Key
FASDKYOPVNHBLU-SSDOTTSWSA-N
FDA UNII
WI638GUS96

Dexpramipexole
A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.
1 2D Structure

Dexpramipexole

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
2.1.2 InChI
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m1/s1
2.1.3 InChI Key
FASDKYOPVNHBLU-SSDOTTSWSA-N
2.1.4 Canonical SMILES
CCCNC1CCC2=C(C1)SC(=N2)N
2.1.5 Isomeric SMILES
CCCN[C@@H]1CCC2=C(C1)SC(=N2)N
2.2 Other Identifiers
2.2.1 UNII
WI638GUS96
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2 Amino 6 Propylaminotetrahydrobenzothiazole

2. 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole

3. 2-amino-6-propylaminotetrahydrobenzothiazole

4. 4,5,6,7-tetrahydro-n6-propyl-2,6-benzothiazole-diamine

5. 6,7-tetrahydro-n6-propyl-2,6-benzothiazolediamine Dihydrochloride Monohydrate

6. Kns 760704

7. Kns-760704

8. Kns760704

9. Mirapex

10. Pramipexol

11. Pramipexol Dihydrobromide, (+-)-isomer

12. Pramipexol Dihydrochloride, (s)-isomer

13. Pramipexol, (+-)-isomer

14. Pramipexol, (r)-isomer

15. Pramipexole

16. Pramipexole Dihydrochloride

17. Pramipexole Dihydrochloride Anhydrous

18. Pramipexole Hydrochloride Monohydrate

19. Sifrol

20. Snd 919

21. Snd 919cl2x

22. Snd-919

23. Snd-919cl2x

24. Snd919cl2x

2.3.2 Depositor-Supplied Synonyms

1. 104632-28-2

2. (r)-pramipexole

3. (r)-n6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine

4. R-(+)-pramipexole

5. (6r)-6-n-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

6. Wi638gus96

7. Kns-760704

8. (r)-pramipexole Dihydrochloride

9. Dexpramipexole Dihydrochloride

10. Dexpramipexole [usan:inn]

11. Unii-wi638gus96

12. Dexpramipexole (usan/inn)

13. Dexpramipexole [inn]

14. Schembl74780

15. Dexpramipexole [usan]

16. Mls006011813

17. Chembl249420

18. Dexpramipexole [who-dd]

19. Dtxsid50146624

20. Bcp12512

21. Zinc3831352

22. 2,6-benzothiazolediamine, 4,5,6,7-tetrahydro-n6-propyl-, (6r)-

23. Bdbm50568780

24. Hy-17355b

25. Stk621530

26. Akos005555111

27. Cs-1196

28. Db15130

29. Ac-36724

30. As-56557

31. Smr004703492

32. D09886

33. F19514

34. Q5268345

35. (6r)-4,5,6,7-tetrahydro-n6-propyl-2,6-benzothiazole-diamine

36. (6r)-n6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

37. (6r)-n~6~-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

38. (r)-4,5,6,7-tetrahydro-6-(propylamino)-benzothiazole-2-amine

39. 2,6-benzothiazolediamine, 4,5,6,7-tetrahydro-n6-propyl-, (r)-

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 211.33 g/mol
Molecular Formula C10H17N3S
XLogP31.9
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count3
Exact Mass211.11431873 g/mol
Monoisotopic Mass211.11431873 g/mol
Topological Polar Surface Area79.2 Ų
Heavy Atom Count14
Formal Charge0
Complexity188
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antioxidants

Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)


Antiparkinson Agents

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)


Dopamine Agonists

Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty